Dexmedetomidine for prevention of skeletal muscle ischaemia-reperfusion injury in patients with chronic limb ischaemia undergoing aortobifemoral bypass surgery: A prospective double-blind randomized controlled study
dc.contributor.author | Kundra, Tanveer Singh | en_US |
dc.contributor.author | Thimmarayappa, Ashwini | en_US |
dc.contributor.author | Dhananjaya, Manasa | en_US |
dc.contributor.author | Manjunatha, N | en_US |
dc.date.accessioned | 2019-12-02T09:42:36Z | |
dc.date.available | 2019-12-02T09:42:36Z | |
dc.date.issued | 2018-01 | |
dc.description.abstract | Background: Dexmedetomidine is a selective α-2 agonist used for sedation. It has also been shown to have myocardial protective effect and prevent ischemia-reperfusion injury in off-pump coronary artery bypass patients. The aim of our study was to assess the effect of dexmedetomidine for prevention of skeletal muscle ischemia-reperfusion injury in patients undergoing aortobifemoral bypass surgery. Methodology: Sixty adult patients (Group dexmedetomidine n = 30, Group normal saline n = 30) undergoing aortobifemoral bypass surgery were recruited over 3 months. Randomization was done using a computer-generated random table. The attending anesthesiologist would be blinded to whether the drug/normal saline was being administered. He would consider each unlabeled syringe as containing dexmedetomidine and calculate the volume to be infused via a syringe pump accordingly. Dexmedetomidine infusion (1 mcg/kg) over 15 minutes was given as a loading dose, followed by maintenance infusion of 0.5 mcg/kg/h till 2 h postprocedure in Group dexmedetomidine (D) while the same volume of normal saline was given in the control Group C till 2 h postprocedure. Creatine phosphokinase (CPK) values were noted at baseline (T0), 6 h (T1), 12 h (T2), and 24 h (T3) after the procedure. Hemodynamic variables (heart rate [HR] and mean blood pressure [MAP]) were recorded at T0, T1, T2, and T3. Results were analyzed using unpaired Student's t-test, P < 0.05 was considered statistically significant. Results: MAP and HR significantly decreased in Group D as compared to control group (P < 0.05). However, the decrease was never <20% of the baseline. The CPK values at 6, 12, and 24 h were statistically significant between the two groups. Conclusion: Dexmedetomidine prevents skeletal muscle ischemia-reperfusion injury in patients undergoing aortobifemoral bypass surgery. | en_US |
dc.identifier.affiliations | Department of Cardiac Anaesthesia, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, Karnataka, India | en_US |
dc.identifier.citation | Kundra Tanveer Singh, Thimmarayappa Ashwini, Dhananjaya Manasa, Manjunatha N. Dexmedetomidine for prevention of skeletal muscle ischaemia-reperfusion injury in patients with chronic limb ischaemia undergoing aortobifemoral bypass surgery: A prospective double-blind randomized controlled study. Annals of Cardiac Anaesthesia. 2018 Jan; 21(1): 22-25 | en_US |
dc.identifier.issn | 0971-9784 | |
dc.identifier.place | India | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/185698 | |
dc.language | en | en_US |
dc.publisher | Wolters Kluwer - Medknow | en_US |
dc.relation.issuenumber | 1 | en_US |
dc.relation.volume | 21 | en_US |
dc.source.uri | https://dx.doi.org/10.4103/aca.ACA_113_17 | en_US |
dc.subject | Aortobifemoral bypass | en_US |
dc.subject | dexmedetomidine | en_US |
dc.subject | ischemia‑reperfusion injury | en_US |
dc.title | Dexmedetomidine for prevention of skeletal muscle ischaemia-reperfusion injury in patients with chronic limb ischaemia undergoing aortobifemoral bypass surgery: A prospective double-blind randomized controlled study | en_US |
dc.type | Journal Article | en_US |
Files
Original bundle
1 - 1 of 1